all report title image
  • Published On : Sep 2020
  • Code : CMI1178
  • Industry : Pharmaceutical
  • Pages : 197
  • Formats :

Urinary tract infection is the infection of bladder, urethra, ureter and kidneys and occurs due to colonization of microbial pathogen in the bladder or kidneys. There are two types of urinary tract infections: complicated urinary tract infection and uncomplicated urinary tract infection.

The global urinary tract infection treatment market is estimated to account for US$ 10,170.8 Mn in terms of value and is expected to reach US$ 11,827.8 Mn by the end of 2027.

Global Urinary Tract Infection Treatment Market: Drivers

High prevalence of urinary tract infection is expected to propel growth of the global urinary tract infection market over the forecast period. For instance, according to the study “Prevalence of Bacterial Urinary Tract Infections and Associated Factors among Patients Attending Hospitals in Bushenyi District, Uganda”, published in February 2019, the prevalence of UTI was 32.2% among the study.     

Moreover, R&D of novel class of antibiotics for urinary tract infections is also expected to aid in growth of the market. For instance, in August 2020, researchers at the California Polytechnic State University reported development of a new class of antibiotics for urinary tract infections, which targets bacterial iron acquisition, at the American Chemical Society (ACS) Fall 2020 Virtual Meeting & Expo.

Statistics:

Quinolones held dominant position in the global urinary tract infection treatment market in 2019, accounting for 37.7% share in terms of value, followed by Cephalosporin and Penicillin & Combinations, respectively.

Figure 1. Global Urinary Tract Infection Treatment Market Share (%), by Value, by Drug Type, 2019

Urinary Tract Infection Treatment  | Coherent Market Insights

Global Urinary Tract Infection Treatment Market: Restraints

Complex regulatory requirements are expected to hinder growth of the global urinary tract infection treatment market. The clinical trial of an antibiotic differs from other therapeutic drugs with respect to the clinical approval approach such as clinical trial design, interpretation and analysis. The sponsor has to conduct non-inferiority trials to get the approval with along with currently registered antibacterial drugs. The clinical trials for designing antibacterial drugs is complex and require an informative, ethical and scientific approach. These factors are expected to negatively impact market growth over the forecast period.

Moreover, low investment in research & development is also expected to limit the market growth.  Many companies have stopped or decreased R&D activities in developing antibiotics as it has poor return on investment. This is attributed to the duration of treatment being short and these drugs cure the disease most of the time. Only a few companies such as GlaxoSmithKline, Pfizer, Cipla are investing in antibacterial discovery programs. Low investment on R&D for new drugs is expected to hamper growth of the market over the forecast period as most bacteria are becoming resistant to currently available antibiotics.

CMI table icon

Urinary Tract Infection Treatment Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 9,971.9 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 2.2% 2027 Value Projection: US$ 11,827.8 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Drug Type:
    • Penicillin & Combinations: Amoxicillin, Amoxicillin+ Clavulanate, Potassium, Others.
    • Quinolones: Ciprofloxacin, Levofloxacin, Nalidixic acid, Norfloxacin, Others.
    • Cephalosporin: Ceftriaxone, Cefuroxime, Cefixime, Cephalexin.
    • Aminoglycoside Antibiotics: Amikacin, Gentamicin.
    • Sulphonamides (Sulfamethoxazole + Trimethoprim), Azoles and Amphotericin B, Tetracycline (Doxycycline), Nitrofurans (Nitrofurantoin), Other.
  • By Disease Indication: Complicated UTI, Recurring Complicated UTI, Uncomplicated UTI, Neurogenic Bladder Infections.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Cipla Ltd., Johnson & Johnson, Bayer AG, Pfizer Inc., GlaxoSmithKline, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., Iterum Therapeutics plc, Novartis AG AstraZeneca Plc, Allecra Therapeutics, Healthy.io, Shionogi Inc., Spero Therapeutics, Inc., and Venatorx Pharmaceuticals.

Growth Drivers:
  • High prevalence of urinary tract infection
  • Availability of number of drugs
Restraints & Challenges:
  • Complex regulatory requirements
  • Low research and development

Global Urinary Tract Infection Treatment Market: Opportunities  

R&D of in urinary tract infections is expected to offer lucrative growth opportunities for players in the global urinary tract infection treatment market. For instance, in May 2020, researchers from Vrije Universiteit Amsterdam, The Netherlands, reported that in an intention-to-diagnose high-risk pediatric population, urinary tract infections could be discriminated from non- urinary tract infection by volatile organic compounds profiling, using an electronic nose.

Moreover, high prevalence of urinary tract infections in emerging economies is also expected to aid in growth of the market. For instance, the study, ‘Prevalence of urinary tract infections and current scenario of antibiotic susceptibility pattern of bacteria causing UTI’ conducted at the Microbiology department of a tertiary health care hospital in Mumbai and published in 2018, the overall prevalence of UTI was 33.54% of which 66.78% were females and 33.22% were from males.

The global urinary tract infection treatment market was valued at US$ 9,971.9 Mn in 2019 and is forecast to reach a value of US$ 11,827.8 Mn by 2027 at a CAGR of 2.2% between 2020 and 2027.

Figure 2. Global Urinary Tract Infection Treatment Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

Urinary Tract Infection Treatment  | Coherent Market Insights

Market Trends/Key Takeaways

Major players in the global urinary tract infection treatment market are focused on R&D of new therapies in order to expand their product portfolio. For instance, in February 2020, Allecra Therapeutics, a France-based pharmaceutical company, announced that its Exblifep (cefepime-enmetazobactam), a combination of a novel extended-spectrum beta-lactamase inhibitor, enmetazobactam, and the fourth-generation cephalosporin cefepime, achieved primary endpoints in a clinical trial for complicated urinary tract infections (cUTI).

Major players in the market are also focused on adopting partnership strategies to enhance their market share. For instance, in July 2019, Healthy.io, a smartphone camera-based solutions developer, announced an agreement with Walgreens Boots Alliance, Inc. placing Healthy.io's Dip UTI test kits in Boots pharmacies throughout the United Kingdom.

Global Urinary Tract Infection Treatment Market: Competitive Landscape

Major players operating in the global urinary tract infection treatment market include, Cipla Ltd., Johnson & Johnson, Bayer AG, Pfizer Inc., GlaxoSmithKline, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., Iterum Therapeutics plc, Novartis AG AstraZeneca Plc, Allecra Therapeutics, Healthy.io, Shionogi Inc., Spero Therapeutics, Inc., and Venatorx Pharmaceuticals.

Global Urinary Tract Infection Treatment Market: Key Developments

Major players in the global urinary tract infection treatment market are focused on R&D of new therapies in order to expand their product portfolio. For instance, in May 2020, Spero Therapeutics, Inc. announced the completion of patient enrollment in its Phase 3 clinical trial, ADAPT-PO, of tebipenem HBr for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP).

Urinary Tract Infection (UTI) is caused when bacteria enters the urethra and infects the urinary bladder, causing severe health issues. UTI infections are common health problems in females than in males with biologic factors accounting as the major cause. Antibiotics are usually the first line of treatment prescribed by doctors for urinary tract infections. According to the site of manifestation by the microbe, infections are classified as cystitis (bladder), urethritis (urethra), prostatitis (prostate) or pyelonephritis (kidney). Painful and increased frequency of urination, excessive and involuntary passing of urine at night are the common symptoms associated with UTI. Hospitalized patients using urinary catheters are at a higher risk for developing UTI.

Restraints of the Global Urinary Tract Infection Treatment Market

Major factors hampering the growth of the urinary tract infection treatment market during the forecast period constitutes of low adoption of internet in some emerging economies.

Key features of the study:

  • This report provides in-depth analysis of the global urinary tract infection treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global urinary tract infection treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Cipla Ltd., Johnson & Johnson, Bayer AG, Pfizer Inc., GlaxoSmithKline, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., Iterum Therapeutics plc, Novartis AG AstraZeneca Plc, Allecra Therapeutics, Healthy.io, Shionogi Inc., Spero Therapeutics, Inc., and Venatorx Pharmaceuticals.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global urinary tract infection treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Urinary Tract Infection Treatment Market, By Drug Type:
    • Penicillin & Combinations
      • Amoxicillin
      • "Amoxicillin+ Clavulanate
      • Potassium"
      • Others
    • Quinolones
      • Ciprofloxacin
      • Levofloxacin
      • Nalidixic acid
      • Norfloxacin
      • Others
    • Cephalosporin
      • Ceftriaxone
      • Cefuroxime
      • Cefixime
      • Cephalexin
    • Aminoglycoside Antibiotics
      • Amikacin
      • Gentamicin
    • "Sulphonamides (Sulfamethoxazole +
    • Trimethoprim)"
    • Azoles and Amphotericin B
    • Tetracycline (Doxycycline)
    • Nitrofurans (Nitrofurantoin)
    • Other
  • Global Urinary Tract Infection Treatment Market, By Disease Indication:
    • Complicated UTI
    • Recurring Complicated UTI
    • Uncomplicated UTI
    • Neurogenic Bladder Infections
  • Global Urinary Tract Infection Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Urinary Tract Infection Treatment Market, By Geography:
    • North America
      • By Drug Type
        • Penicillin & Combinations
          • Amoxicillin
          • "Amoxicillin+ Clavulanate
          • Potassium"
          • Others
        • Quinolones
          • Ciprofloxacin
          • Levofloxacin
          • Nalidixic acid
          • Norfloxacin
          • Others
        • Cephalosporin
          • Ceftriaxone
          • Cefuroxime
          • Cefixime
          • Cephalexin
        • Aminoglycoside Antibiotics
          • Amikacin
          • Gentamicin
        • "Sulphonamides (Sulfamethoxazole +
        • Trimethoprim)"
        • Azoles and Amphotericin B
        • Tetracycline (Doxycycline)
        • Nitrofurans (Nitrofurantoin)
        • Other
      • By Disease Indication
        • Complicated UTI
        • Recurring Complicated UTI
        • Uncomplicated UTI
        • Neurogenic Bladder Infections
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Drug Type
        • Penicillin & Combinations
          • Amoxicillin
          • "Amoxicillin+ Clavulanate
          • Potassium"
          • Others
        • Quinolones
          • Ciprofloxacin
          • Levofloxacin
          • Nalidixic acid
          • Norfloxacin
          • Others
        • Cephalosporin
          • Ceftriaxone
          • Cefuroxime
          • Cefixime
          • Cephalexin
        • Aminoglycoside Antibiotics
          • Amikacin
          • Gentamicin
        • "Sulphonamides (Sulfamethoxazole +
        • Trimethoprim)"
        • Azoles and Amphotericin B
        • Tetracycline (Doxycycline)
        • Nitrofurans (Nitrofurantoin)
        • Other
      • By Disease Indication
        • Complicated UTI
        • Recurring Complicated UTI
        • Uncomplicated UTI
        • Neurogenic Bladder Infections
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type
        • Penicillin & Combinations
          • Amoxicillin
          • "Amoxicillin+ Clavulanate
          • Potassium"
          • Others
        • Quinolones
          • Ciprofloxacin
          • Levofloxacin
          • Nalidixic acid
          • Norfloxacin
          • Others
        • Cephalosporin
          • Ceftriaxone
          • Cefuroxime
          • Cefixime
          • Cephalexin
        • Aminoglycoside Antibiotics
          • Amikacin
          • Gentamicin
        • "Sulphonamides (Sulfamethoxazole +
        • Trimethoprim)"
        • Azoles and Amphotericin B
        • Tetracycline (Doxycycline)
        • Nitrofurans (Nitrofurantoin)
        • Other
      • By Disease Indication
        • Complicated UTI
        • Recurring Complicated UTI
        • Uncomplicated UTI
        • Neurogenic Bladder Infections
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Drug Type
        • Penicillin & Combinations
          • Amoxicillin
          • "Amoxicillin+ Clavulanate
          • Potassium"
          • Others
        • Quinolones
          • Ciprofloxacin
          • Levofloxacin
          • Nalidixic acid
          • Norfloxacin
          • Others
        • Cephalosporin
          • Ceftriaxone
          • Cefuroxime
          • Cefixime
          • Cephalexin
        • Aminoglycoside Antibiotics
          • Amikacin
          • Gentamicin
        • "Sulphonamides (Sulfamethoxazole +
        • Trimethoprim)"
        • Azoles and Amphotericin B
        • Tetracycline (Doxycycline)
        • Nitrofurans (Nitrofurantoin)
        • Other
      • By Disease Indication
        • Complicated UTI
        • Recurring Complicated UTI
        • Uncomplicated UTI
        • Neurogenic Bladder Infections
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East:
      • By Drug Type
        • Penicillin & Combinations
          • Amoxicillin
          • "Amoxicillin+ Clavulanate
          • Potassium"
          • Others
        • Quinolones
          • Ciprofloxacin
          • Levofloxacin
          • Nalidixic acid
          • Norfloxacin
          • Others
        • Cephalosporin
          • Ceftriaxone
          • Cefuroxime
          • Cefixime
          • Cephalexin
        • Aminoglycoside Antibiotics
          • Amikacin
          • Gentamicin
        • "Sulphonamides (Sulfamethoxazole +
        • Trimethoprim)"
        • Azoles and Amphotericin B
        • Tetracycline (Doxycycline)
        • Nitrofurans (Nitrofurantoin)
        • Other
      • By Disease Indication
        • Complicated UTI
        • Recurring Complicated UTI
        • Uncomplicated UTI
        • Neurogenic Bladder Infections
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type
        • Penicillin & Combinations
          • Amoxicillin
          • "Amoxicillin+ Clavulanate
          • Potassium"
          • Others
        • Quinolones
          • Ciprofloxacin
          • Levofloxacin
          • Nalidixic acid
          • Norfloxacin
          • Others
        • Cephalosporin
          • Ceftriaxone
          • Cefuroxime
          • Cefixime
          • Cephalexin
        • Aminoglycoside Antibiotics
          • Amikacin
          • Gentamicin
        • "Sulphonamides (Sulfamethoxazole +
        • Trimethoprim)"
        • Azoles and Amphotericin B
        • Tetracycline (Doxycycline)
        • Nitrofurans (Nitrofurantoin)
        • Other
      • By Disease Indication
        • Complicated UTI
        • Recurring Complicated UTI
        • Uncomplicated UTI
        • Neurogenic Bladder Infections
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Cipla Ltd.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Johnson & Johnson
    • Bayer AG
    • Pfizer Inc.
    • GlaxoSmithKline
    • Boehringer Ingelheim
    • F. Hoffmann-La Roche Ltd.
    • Iterum Therapeutics plc
    • Novartis AG
    • AstraZeneca Plc
    • Allecra Therapeutics
    • Shionogi Inc.
    • Spero Therapeutics, Inc.
    • Venatorx Pharmaceuticals.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global urinary tract infection treatment market was valued at US$ 9,971.9 Mn in 2019 and is forecast to reach a value of US$ 11,827.8 Mn by 2027 at a CAGR of 2.2% between 2020 and 2027.
Major factor driving the growth of global urinary tract infection treatment market during the forecast period include high prevalence of urinary tract infection, and availability of number of drugs.
Major factors hampering the growth of the urinary tract infection treatment market during the forecast period constitutes of complex regulatory requirements, and low research and development.
Quinolones held dominant position in the global urinary tract infection treatment market in 2019.
North America Urinary Tract Infection Treatment market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are Cipla Ltd., Johnson & Johnson, Bayer AG, Pfizer Inc., GlaxoSmithKline, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., Iterum Therapeutics plc, Novartis AG AstraZeneca Plc, Allecra Therapeutics, Shionogi Inc., Spero Therapeutics, Inc., and Venatorx Pharmaceuticals.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo